APL 1030
Alternative Names: APL-1030; APL-1030-ITLatest Information Update: 28 Mar 2023
At a glance
- Originator Apellis Pharmaceuticals
- Class Neuroprotectants; Proteins
- Mechanism of Action Complement C3 inhibitors; Complement C3b inactivator protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders